CA2480811A1 - Acide nucleique et proteine correspondante 213p1f11 que l'on utilise dans le traitement et la detection du cancer - Google Patents

Acide nucleique et proteine correspondante 213p1f11 que l'on utilise dans le traitement et la detection du cancer Download PDF

Info

Publication number
CA2480811A1
CA2480811A1 CA002480811A CA2480811A CA2480811A1 CA 2480811 A1 CA2480811 A1 CA 2480811A1 CA 002480811 A CA002480811 A CA 002480811A CA 2480811 A CA2480811 A CA 2480811A CA 2480811 A1 CA2480811 A1 CA 2480811A1
Authority
CA
Canada
Prior art keywords
protein
amino acid
cancer
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002480811A
Other languages
English (en)
Inventor
Pia M. Challita-Eid
Arthur B. Raitano
Mary Faris
Rene S. Hubert
Robert Kendall Morrison
Wangmao Ge
Aya Jakobovits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2480811A1 publication Critical patent/CA2480811A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

L'invention concerne un nouveau gène (que l'on appelle 213P1F11) et sa protéine codée, et ses variantes, le gène de cette invention ayant une expression spécifique au tissu dans un tissu adulte normal et dont l'expression dans les cancers énumérés dans le tableau I s'avère aberrante. En conséquence, le gène 213P1F11 fournit une cible de diagnostic, de pronostic, profilactique et/ou thérapeutique pour le cancer. Le gène 213P1F11 ou son fragment, ou sa protéine codée ou ses variantes ou son fragment peuvent être utilisés pour provoquer une réponse immunitaire humorale ou cellule. On peut utiliser des anticorps ou des lymphocytes T réagissant au gène 213P1F11 dans l'immunisation active ou passive.
CA002480811A 2002-04-01 2002-04-01 Acide nucleique et proteine correspondante 213p1f11 que l'on utilise dans le traitement et la detection du cancer Abandoned CA2480811A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/010220 WO2003085121A2 (fr) 2002-04-01 2002-04-01 Acide nucleique et proteine correspondante 213p1f11 que l'on utilise dans le traitement et la detection du cancer

Publications (1)

Publication Number Publication Date
CA2480811A1 true CA2480811A1 (fr) 2003-10-16

Family

ID=28789615

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002480811A Abandoned CA2480811A1 (fr) 2002-04-01 2002-04-01 Acide nucleique et proteine correspondante 213p1f11 que l'on utilise dans le traitement et la detection du cancer

Country Status (5)

Country Link
EP (1) EP1578980A4 (fr)
AU (1) AU2002258689C1 (fr)
CA (1) CA2480811A1 (fr)
IL (2) IL164326A0 (fr)
WO (1) WO2003085121A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040019915A1 (en) 2002-04-01 2004-01-29 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
MX343490B (es) 2008-07-16 2016-11-08 Inst For Res In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos.
CN114262683B (zh) * 2022-03-01 2022-06-17 中国科学院动物研究所 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011219A1 (fr) * 1996-09-11 1998-03-19 Incyte Pharmaceuticals, Inc. Proteines membranaires associees a des maladies (damp)
US6340740B1 (en) * 1997-08-26 2002-01-22 Thomas Jefferson University Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use
US6432628B1 (en) * 1997-08-26 2002-08-13 Thomas Jefferson University Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use
CZ2001149A3 (cs) * 1998-07-14 2002-02-13 Corixa Corporation Prostředky a způsoby pro terapii a diagnostiku karcinomu prostaty
WO2000020638A2 (fr) * 1998-10-02 2000-04-13 Urogenesys, Inc. Procedes et compositions pour le diagnostic et la therapie du cancer de la prostate
WO2001059110A2 (fr) * 2000-02-08 2001-08-16 Agensys, Inc. 34p3d7: proteine specifique aux tissus hautement exprimes dans le cancer de la prostate
WO2001081595A2 (fr) * 2000-04-27 2001-11-01 Knoll Gmbh Compositions a base de caspase-14 d'origine humaine

Also Published As

Publication number Publication date
AU2002258689B8 (en) 2003-10-20
WO2003085121A2 (fr) 2003-10-16
EP1578980A4 (fr) 2013-01-02
AU2002258689B2 (en) 2007-08-16
WO2003085121A9 (fr) 2012-01-12
AU2002258689A1 (en) 2003-10-20
IL164326A (en) 2011-03-31
AU2002258689C1 (en) 2008-04-24
IL164326A0 (en) 2005-12-18
EP1578980A2 (fr) 2005-09-28

Similar Documents

Publication Publication Date Title
US7641905B2 (en) Methods of inducing an immune response
US20070298424A1 (en) Nucleic acids and corresponding proteins entitled 273P4B7 useful in treatment and detection of cancer
CA2459318A1 (fr) Acide nucleique et proteine correspondante designes par steap-1 utiles dans le traitement et la detection du cancer
US8168187B2 (en) Nucleic acid and corresponding protein entitled 184P1E2 useful in treatment and detection of cancer
US8497351B2 (en) Nucleic acid and corresponding protein entitled 162P1E6 useful in treatment and detection of cancer
US8173132B2 (en) Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer
CA2440658A1 (fr) Acide nucleique et proteine correspondante denommes 125p5c8 utiles dans le traitement et la detection de cancers
US7459539B2 (en) Antibody that binds zinc transporter protein 108P5H8
WO2002014361A2 (fr) Acides nucleiques et proteines correspondantes appeles 83p2h3 et catrf2e11 utiles dans le traitement et la detection du cancer
US7601825B2 (en) Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer
CA2480811A1 (fr) Acide nucleique et proteine correspondante 213p1f11 que l'on utilise dans le traitement et la detection du cancer
CA2440147A1 (fr) Acide nucleique et proteine correspondante, appelee 121p1f1, utilisee dans le traitement et le depistage du cancer
CA2443088C (fr) Acide nucleique et proteine correspondante appele 121p2a3 utile pour le traitement et la detection des cancers
CA2458915A1 (fr) Acide nucleique et proteine correspondante appelee 205p1b5 utiles dans le traitement et la detection du cancer
WO2002014501A2 (fr) Acides nucleiques et proteines correspondantes appelees phor1-a11 et phor1-f5d6 utiles dans le traitement et la detection du cancer
CA2479049A1 (fr) Acide nucleique et proteine correspondante appelee 238p1b2 utile dans le traitement et la detection du cancer

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150120